Ora, Inc. Partners with the North West London Clinical Trials Alliance to Accelerate Patient Access to Cutting-Edge Ophthalmology Treatments
Ora, Inc., the world’s leading Clinical Research Organization (CRO) for ophthalmology pharmaceutical and device development, announced today its partnership with the North West London Clinical Trials Alliance (NWL Clinical Trials Alliance), a collaboration between clinical trial teams that aims to improve access to and the quality of clinical research in the region.
This strategic partnership comes at a pivotal time as the UK government emphasizes the importance of innovative partnerships and encourages increased, multi-sector collaboration. The partnership between Ora and the NWL Clinical Trials Alliance directly supports this initiative bringing together academia, industry and the NHS to provide better solutions that will address the gap in patient-access to cutting-edge treatment options.
“Ora and the NWL Clinical Trials Alliance share a common goal: improve access to, and the quality of, clinical research in Europe,” said Stuart Abelson, CEO Ora. “Ora’s well-established leadership position in ophthalmology research, coupled with the reach and relationships established by the NWL Clinical Trials Alliance, will provide our sponsors with an increased level of confidence to deliver European-based early and late-phase research studies.”
For sponsors planning or considering trial delivery in Europe, Ora and the NWL Clinical Trials Alliance will provide:
- Comprehensive analysis of country and site selection, that includes candid feedback based on open and honest communication with study sites.
- Access to a diverse group of study participants eager to receive new treatment options.
- Operational excellence delivered by a seasoned team of ophthalmology-focused resources committed to delivering trials with speed, efficiency, quality, and cost-savings.
“We are honoured to partner with a globally recognized leader in ophthalmology research,” said Dr Suki Balendra, director of NWL Clinical Trials Alliance. “Collaborating with Ora not only improves outcomes for historically underrepresented patient populations but provides an opportunity to explore new and innovative ways to increase clinical trial access for all patients. Europe is in a position to accelerate getting drugs to market faster, while simultaneously helping to build a robust and sustainable clinical research ecosystem beyond the US", she continued.
About Ora, Inc.
Ora is the world's leading full-service ophthalmic drug and device development firm with offices in North America, South America, Europe, Australia, and Asia. For over 45 years, we have proudly helped our clients earn more than 82 product approvals. We support a wide array of organizations, from start-ups to global pharmaceutical and device companies, to efficiently bring their new products from concept to market. Ora's pre-clinical and clinical models, unique methodologies, and global regulatory strategies have been refined and proven across thousands of global projects. We bring together the world's most extensive and experienced team of ophthalmic experts, R&D professionals, and management executives to maximize the value of new product initiatives. For more information, please visit www.oraclinical.com, like us on Facebook, and follow us on LinkedIn
Ora® and Ora Logo are registered trademarks of Ora, Inc.
About North West London Clinical Trials Alliance
The North West London Clinical Trials Alliance is dedicated to delivering commercial and non-commercial sponsored clinical trials – utilising existing and purpose-designed facilities to successfully deliver both early and late-phase research. It aims to increase regional capacity for delivering commercial clinical research, as well as to improve the ease and speed of research delivery, patient access to clinical research and patient opportunities for early access to cutting edge treatment and therapies that are not yet widely available through the NHS. This will be achieved through collaborative working, using our understanding of the needs and priorities of life science companies and our strong regional team ethos to work in a harmonised manner across centres. The ophthalmology unit at London North West University Healthcare NHS Trust, which is part of the North West London Clinical Trials Alliance, is recognised nationally as one of the leaders in delivery of commercial trials and is committed to widening access to novel and innovative treatments for the UK’s diverse communities to improve on health outcomes.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230712806839/en/
Contact information
Media
Claire Russell
crussell@oraclinical.com
+1 (919) 597-9029
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
RTL Luxembourg Expands Deployment of Verimatrix Technologies to Protect Premier Auto Racing Against Piracy11.9.2025 18:45:00 EEST | Press release
Regulatory News: Verimatrix, (Euronext Paris: VMX), a leading provider of security solutions for a safer connected world, today announced that RTL Luxembourg, the country’s leading media company, has further expanded its use of Verimatrix anti-piracy tools to now include the full Streamkeeper suite of solutions. Initially deploying Streamkeeper Multi-DRM, RTL Luxembourg also recently implemented Counterspy, Deepscan and Watermarking solutions – the industry’s latest set of powerful tools that help further bolster proactive protections for RTL’s motorsport content revenue. It was announced in April 2024 that RTL Luxembourg selected Verimatrix Streamkeeper Multi-DRM to ensure that RTL Luxembourg remained in full control of its valuable digital assets while also consistently keeping costs low and preventing unneeded technical complexities. With the addition of Verimatrix’s Counterspy, RTL Luxembourg further expands its ability to detect unauthorized content distribution in real-time, depl
Xylem and Amazon Partner on Smart Water Upgrades to Save More Than 1.3 Billion Liters Annually in Mexico11.9.2025 17:00:00 EEST | Press release
Residents in Mexico City and Monterrey will soon enjoy more reliable water supply as the two cities launch groundbreaking infrastructure upgrades to save over 1.3 billion liters of water a year – easing pressure from the rapid urbanization and persistent drought conditions that have strained local water systems. The two cities are working in partnership with global water technology company Xylem (NYSE: XYL) and Amazon (NASDAQ: AMZN) to deploy Xylem Vue, an advanced software platform that applies data and analytics to detect leaks, cut water losses and improve residents’ water supply. The projects are estimated to save upwards of 800 million liters of water a year in Mexico City and 560 million liters a year in Monterrey. “In a water-stressed region, where every liter counts, recovering more than a billion liters of water each year is a game-changer,” said Jaime Barba, General Manager, Xylem Vue. “Working with Amazon and the local water utilities, we are using data to give these cities
HTEC Partners with World Economic Forum11.9.2025 16:56:00 EEST | Press release
HTEC, a global digital engineering and product development company, has today announced that it has joined the World Economic Forum’s (WEF) Centre for AI Excellence. HTEC will contribute to the community through its expertise and thought leadership to help advance AI adoption and AI innovation across its core industries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250911910448/en/ HTEC Partners with World Economic Forum to bring AI expertise to help with industry transformation and real-world outcomes WEF’s Centre for AI Excellence is bringing together leading industry organisations and experts to work together to advance the pace and positive impact AI can have in economies and societies. Its goal is to unlock transformative potential in an equitable and human-centered way, which is well aligned with HTEC’s principles and values. As an AI-first organization, HTEC blends deep engineering expertise with strategic insight.
Alipay Tap! Users Reach 200 Million, Expands to Over 1,000 Scenarios Beyond Payments11.9.2025 16:31:00 EEST | Press release
Alipay announced today at the 2025 INCLUSION · Conference on the Bund in Shanghai that its QR code-based contactless payment and engagement solution, Alipay Tap!, has rapidly grown its user base to 200 million since its launch in China in June 2024. The milestone comes just months after surpassing 100 million users in April 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250911881010/en/ With Alipay Tap!, users can open a vending machine with a simple tap Designed to be simpler than QR code scanning, Alipay Tap! lets users complete a transaction or access a service by simply tapping their unlocked phone on a merchant’s terminal or Alipay Tap! Tag, eliminating the need to open an app, scan a code, or navigate multiple screens. As Alipay evolves from a digital wallet into a comprehensive platform connecting 1 billion consumers with 80 million merchants nationwide, Alipay Tap! has become a hassle-free gateway to its ecosys
Vertex Scientists Awarded the 2025 Lasker~DeBakey Clinical Medical Research Award for Pioneering Discoveries in Cystic Fibrosis11.9.2025 16:05:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Senior Vice President Paul Negulescu has been named as one of the winners of this year’s Lasker~DeBakey Clinical Medical Research Award for his role “in the development of a novel, life-saving treatment for cystic fibrosis (CF) — namely, a triple-drug combination therapy, TRIKAFTA®, that has helped countless people with this genetic disease.” Dr. Negulescu is one of three awardees, alongside Jesús (Tito) González, a former Vertex scientist, and Michael Welsh, Professor of Internal Medicine-Pulmonary, Critical Care and Occupational Medicine, University of Iowa. The prize honors the groundbreaking work of Dr. Negulescu, Dr. González and the entire Vertex team who discovered and developed the first and only approved medicines that address the underlying cause of CF. To date, Vertex has brought five transformational medicines to patients with CF which have fundamentally changed the way this disease is treated. “I’m hon
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom